Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (2023)

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (3)

to access My Account features

My account area

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (4)Find similar products:

  • Same active ingredient

  • same company

  • Per ATC-Code

    Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (5)

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (6)show changes

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (7)Add to favorites

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (8)Share via email

Report side effect

Report a suspected adverse reaction or counterfeit product to the MHRA Yellow Card program.

Go toPrednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (9)Property

Back to top

Prednisolone 5 mg soluble tablets

Active substance:

Prednisolone sodium phosphate


ADVANZ PharmaSee contact details



Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (11)

About medicine

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (12)

Prescription Drugs

My account area

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (13)

to access My Account features

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (14)Find similar products:

  • Same active ingredient

  • same company

  • Per ATC-Code

    Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (15)

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (16)show changes

(Video) Unit 4 - Bioavailability

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (17)Add to favorites

Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (18)Share via email

Health Professionals (SmPC)Patienteninformation (PIL)HCP Med-Info


Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (19)This information is intended for healthcare professionals

Last updated on EMC:20 January 2022

Quick links

unwanted effectsPharmacological propertiesinteractionsdosagecontraindicationsexcipients

Print SmPC information

1. Name of the drug

Prednisolone 5 mg soluble tablets

2. Qualitative and quantitative composition

Each tablet contains 5 mg prednisolone as the sodium phosphate ester.

Excipients with a known effect

Each tablet contains 37.6 mg sodium and 4 mg sodium benzoate (E211).

For the full list of excipients see section 6.1.

3. Dosage form

Soluble tablet

Pink, flat, round, soluble tablets debossed with “λ5” and break mark on same side.

The tablet can be divided into equal doses.

4. Clinical Information
4.1 Areas of application

Prednisolone 5 mg soluble tablets are indicated in adults and children.

A variety of diseases can sometimes require corticosteroid therapy. Some of the main indications are:

• Bronchial asthma, severe hypersensitivity reactions, anaphylaxis;

• Rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, mixed collagenosis (excluding systemic sclerosis), polyarteritis nodosa;

• inflammatory skin diseases, including pemphigus vulgaris, bullous pemphigoid and pyoderma gangrenosum;

• Minimal change nephrotic syndrome, acute interstitial nephritis;

• Ulcerative colitis, Crohn's disease; Sarcoidosis;

• rheumatic carditis;

• Hemolytic anemia (autoimmune), acute lymphoblastic and chronic lymphocytic leukemia, malignant lymphoma, multiple myeloma, idiopathic thrombocytopenic purpura;

• Immunosuppression in transplantation.

4.2 Dosage and method of administration


The lowest dose that gives an acceptable result should be used (see section 4.4); If it is possible to reduce the dosage, it must be done gradually. With prolonged therapy, intercurrent diseases, trauma or surgical intervention require a temporary increase in dose; If corticosteroids are discontinued after prolonged therapy, they may need to be temporarily reintroduced.

Adult:The dose used depends on the disease, its severity and the clinical response obtained. The following treatment regimens are for guidance only. Split dosing is commonly used.

Short-term treatment:20 to 30 mg daily for the first few days, then reducing the daily dose by 2.5 or 5 mg every two to five days depending on response.

Rheumatoide Arthritis:7.5 to 10 mg daily. The lowest effective dose is used for maintenance therapy.

Most other conditions:10 to 100 mg daily for one to three weeks, then tapering to the minimum effective dose.

Pediatric Population

Fractions of the adult dose can be used (eg, 75% at 12 years, 50% at 7 years, and 25% at 1 year), but clinical factors must be given due consideration.

Prednisolone tablets can be given early in the treatment of acute asthma attacks in children. For children over 5 years old, use a dose of 30-40 mg of prednisolone. For children aged 2-5 years use a dose of 20 mg prednisolone. Those already on maintenance steroid tablets should receive 2 mg/kg prednisolone up to a maximum dose of 60 mg. The dose of prednisolone may be repeated in children who vomit; but intravenous steroids should be considered in children who are unable to retain medications taken orally. Treatment for up to three days is usually sufficient, but the duration of treatment should be tailored to the number of days required for recovery. There is no need to reduce the dose at the end of a short treatment period. If treatment is prolonged, discontinuation should not be abrupt (see section 4.4).

In children under 2 years of age, prednisolone tablets at a dose of 10 mg for up to three days can be used early in the treatment of moderate to severe episodes of acute hospitalized asthma.

(Video) QCS Session #7 - API or Approved Product: Where do we start with veterinary compounds?

type of administration

For oral use only

Prednisolone Soluble tablets are best taken dissolved in water, but they can also be swallowed whole without any problems. The solution dissolved in water must be drunk immediately by the patient.

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

- Systemic infections unless specific anti-infective therapy is used.

- Immunization against live viruses.

- Eye herpes simplex due to possible perforation.

4.4 Special warnings and precautions for use

Discontinuation should not be abrupt in patients who have been receiving more than physiological doses of systemic corticosteroids (approximately 7.5 mg prednisolone or equivalent) for more than three weeks. How dose reduction should be accomplished depends largely on whether the disease is likely to recur when the dose of systemic corticosteroids is reduced. Clinical assessment of disease activity may be required during discontinuation. If disease relapse is unlikely after stopping systemic corticosteroids but HPA suppression is uncertain, systemic corticosteroid doses can be rapidly reduced to physiological doses. Once a daily dose of 7.5 mg prednisolone is reached, the dose reduction should be slower to allow the HPA axis to recover.

Abrupt withdrawal of systemic corticosteroid treatment that has been continued for up to three weeks is appropriate when disease recurrence is considered unlikely. Abrupt withdrawal of doses of up to 40 mg prednisolone or equivalent daily for three weeks is unlikely to result in clinically relevant suppression of the HPA axis in the majority of patients. Systemic corticosteroid therapy should be gradually withdrawn in the following patient groupstaken into accounteven after courses of three weeks or less:

• Patients who have received repeated systemic corticosteroids, particularly if taken for more than three weeks.

• If short-term therapy has been prescribed within one year of cessation of long-term therapy (months or years).

• Patients who may have causes of adrenal insufficiency other than exogenous corticosteroid therapy, or who have discontinued corticosteroids after prolonged therapy, may need to be temporarily re-treated with corticosteroids.

• Patients receiving systemic corticosteroid doses greater than 40 mg prednisolone (or equivalent) daily.

• Patients taking repeated doses in the evening.

Patients should carry "steroid treatment cards" which provide clear advice on the precautions to be taken to minimize risk and give details of the prescribing physician, drug, dosage and duration of treatment.

Adrenal cortical atrophy develops during prolonged therapy and may persist for years after treatment is stopped. Discontinuation of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency and tapered off over weeks or months, depending on the dose and duration of treatment. With prolonged therapy, intercurrent diseases, trauma or surgical intervention require a temporary increase in dose; If corticosteroids are discontinued after prolonged therapy, they may need to be temporarily reintroduced.

HPA axis suppression and other undesirable effects can be minimized by using the lowest effective dose for the minimum period of time and by administering the daily requirement as a single morning dose or, whenever possible, as a single morning dose every other day. Frequent patient review is required to titrate the dose according to disease activity (see section 4.2).

visual disturbance

Visual disturbances have been reported with systemic and topical use of corticosteroids. If a patient presents with symptoms such as blurred vision or other visual disturbances, consideration should be given to referring the patient to an ophthalmologist for evaluation of possible causes other than cataract, glaucoma, or rare diseases such as cataracts. B. Central serous chorioretinopathy (CSCR) may have been reported after use of systemic and topical corticosteroids.

Anti-inflammatory/immunosuppressive effect and infection

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids can result in clinical remission.

Chronic immunosuppression (e.g. as part of organ transplantation) has been associated with an increased risk of malignancy.

Suppression of the inflammatory response and immune function increases susceptibility to infection and its severity. The resulting opportunistic infections can be fatal. The clinical presentation can often be atypical, and serious infections such as septicemia and tuberculosis can be masked and progress to an advanced stage before they are recognized.

Chickenpox is of particular concern as this normally harmless disease can be fatal in immunocompromised patients. Patients with no clear history of chickenpox should be advised to avoid close personal contact with chickenpox or herpes zoster and seek urgent medical attention in the event of exposure. If the patient is a child, parents must receive the above advice. Passive immunization with varicella zoster immunoglobulin (VZIG) is required in exposed non-immunological patients who are receiving systemic corticosteroids or have used them within the past 3 months; this should be given within 10 days of exposure to chickenpox. If the diagnosis of chickenpox is confirmed, the disease requires specialist care and urgent treatment.

Corticosteroids should not be stopped and the dose may need to be increased.

Patients should be advised to take special care to avoid exposure to measles and to seek medical advice immediately if exposed. Prophylaxis with intramuscular normal immunoglobulin may be necessary.

Live vaccines should not be given to people with an impaired immune response caused by high doses of corticosteroids. The antibody response to other vaccines may be reduced.

Because of the potential for fluid retention, caution should be exercised when administering corticosteroids to patients with renal impairment, hypertension, or congestive heart failure.

Corticosteroids can aggravate diabetes mellitus, osteoporosis, hypertension, glaucoma and epilepsy and therefore patients with these disorders or a family history should be monitored frequently.

Caution should be exercised and frequent patient monitoring is required if there is a history of severe mood disorders (particularly a history of steroid psychosis), previous steroid myopathy, peptic ulcer disease, hypothyroidism, recent myocardial infarction, or patients with a history of tuberculosis.

In patients with liver failure, blood levels of corticosteroids may be increased, as with other drugs that are metabolised in the liver. Therefore, frequent monitoring of the patient is required.

Use in the elderly: The common side effects of systemic corticosteroids can become more serious as we age, particularly osteoporosis, hypertension, hypokalemia, diabetes, susceptibility to infection, and thinning of the skin. Close clinical monitoring is required to avoid life-threatening reactions.

Patients and/or carers should be warned that potentially serious psychiatric adverse reactions can occur with systemic steroids (see section 4.8). Symptoms typically appear within a few days or weeks of starting treatment. Risks may be greater at high doses/systemic exposure (see also section 4.5), although dose levels are not predictive of onset, type, severity or duration of reactions. Most side effects resolve with either dose reduction or drug discontinuation, although specific treatment may be required. Patients/carers should be encouraged to seek medical advice if psychiatric symptoms of concern develop, particularly if depressed mood or suicidal thoughts are suspected. Patients/carers should also be aware of possible psychiatric disturbances that may occur either during or immediately after dose taper/withdrawal of systemic steroids, although such reactions have rarely been reported.

Particular caution should be exercised when considering the use of systemic corticosteroids in patients with current or history of severe mood disorders in themselves or in first-degree relatives. These include depressive or manic-depressive illnesses and previous steroid psychosis.

Scleroderma renal crisis

Caution is advised in patients with systemic sclerosis, as an increased incidence of (possibly fatal) scleroderma-renal crisis with hypertension and decreased urinary output is observed with daily doses of 15 mg or more prednisolone. Blood pressure and kidney function (S-creatinine) should therefore be checked routinely. Blood pressure should be carefully monitored if a kidney crisis is suspected.

Pediatric Population

Corticosteroids cause dose-related growth retardation in infancy, childhood, and adolescence, which may be irreversible.


This medicinal product contains 37.6 mg sodium per dose, equivalent to 1.88% of the WHO recommended maximum daily intake of sodium. The maximum daily intake of this product is equivalent to 37.6% of the WHO recommended maximum daily intake for sodium. Prednisolone Soluble Tablets are considered high in sodium. This should be taken into account, especially with a low-salt diet.

This medicine contains 4 mg of benzoate salt in each tablet, which can cause an increase in bilirubinemia, since its displacement from albumin can increase neonatal jaundice, which can develop into kernicterus (deposits of unconjugated bilirubin in the brain tissue).

4.5 Interaction with other medicinal products and other forms of interaction

Concomitant treatment with CYP3A inhibitors, including medicinal products containing cobicistat, is expected to increase the risk of systemic side effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects. In this case, patients should be monitored for systemic corticosteroid side effects.

Rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone, ephedrine and aminoglutethimide increase the metabolism of corticosteroids and their therapeutic effects may be reduced.

Mifepristone can reduce the effects of corticosteroids for 3-4 days.

Erythromycin and ketoconazole can inhibit the metabolism of some corticosteroids.

Ciclosporin increases the plasma concentration of prednisolone. The same effect is possible with ritonavir.

Estrogens and other oral contraceptives may potentiate the effects of glucocorticoids, and dose adjustments may be required when oral contraceptives are added to or removed from a stable dosing regimen.

The desired effects of antidiabetics (including insulin), antihypertensives and diuretics are antagonized by corticosteroids.

(Video) Session 6

The growth-promoting effect of somatotropin can be inhibited by the concomitant use of corticosteroids.

Steroids can reduce the effect of anticholinesterases in myasthenia gravis and cholecystographic X-ray media.

The efficacy of coumarin anticoagulants and warfarin may be enhanced by concomitant corticosteroid therapy and close monitoring of INR or prothrombin time is required to avoid spontaneous bleeding.

Concomitant use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) with corticosteroids increases the risk of gastrointestinal bleeding and ulceration.

Renal clearance of salicylates is increased by corticosteroids and steroid withdrawal can lead to salicylate intoxication.

The hypokalemic effect of acetazolamide, loop diuretics, thiazide diuretics, and carbenoxolone is potentiated by corticosteroids. The risk of hypokalemia is increased with theophylline and amphotericin. Corticosteroids should not be co-administered with amphotericin unless necessary to control response.

The risk of hypokalemia also increases when high doses of corticosteroids are given with high doses of bambuterol, fenoterol, formoterol, ritodrine, salbutamol, salmeterol, and terbutaline. The toxicity of cardiac glycosides is increased when hypokalemia occurs with corticosteroids.

Concomitant use with methotrexate may increase the risk of haematological toxicity.

High doses of corticosteroids impair the immune response, therefore live vaccines should be avoided (see also section 4.4).

4.6 Fertility, pregnancy and lactation


The ability of corticosteroids to cross the placenta varies between drugs, but 88% of prednisolone is inactivated when it crosses the placenta.

Administration of corticosteroids to pregnant animals can cause abnormalities in fetal development, including cleft palate, intrauterine growth retardation, and effects on brain growth and development. There is no evidence that corticosteroids lead to an increased incidence of congenital anomalies such as cleft palate/lip in humans. However, with prolonged or repeated use during pregnancy, corticosteroids may increase the risk of intrauterine growth retardation.

Hypoadrenalism can theoretically occur in the newborn after prenatal exposure to corticosteroids, but it usually resolves spontaneously after birth and is rarely clinically relevant. As with all drugs, corticosteroids should only be prescribed if the benefits to the mother and child outweigh the risks. However, when corticosteroids are essential, patients with normal pregnancies can be treated as if they were in the non-pregnant state.

Patients with preeclampsia or fluid retention should be closely monitored.

A decrease in hormone levels has been described in pregnancy, but the significance of this finding is not clear.


Corticosteroids are excreted in small amounts in breast milk. However, doses of up to 40 mg prednisolone daily are unlikely to produce systemic effects in the infant. Infants born to mothers taking higher doses than this may have some degree of adrenal suppression, but the benefits of breastfeeding likely outweigh any theoretical risk.


No data available

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Adverse Reactions

The frequency of foreseeable adverse reactions, including hypothalamic-pituitary-adrenal (HPA) suppression, correlates with the relative potency of the medicinal product, dose, timing of administration and duration of treatment (see section 4.4).

Adverse reactions are listed by system organ class. The following side effects may be associated with long-term systemic corticosteroid use with the following frequencies:

Not known (cannot be estimated from the available data)

class system organ

unwanted effects

infections and pests

Increased susceptibility and severity of infections with suppression of clinical symptoms and signs, opportunistic infections, recurrence of dormant tuberculosis (see section 4.4).

Neoplasms benign, malignant, and unspecified (including cysts and polyps)

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids can result in clinical remission.

Blood and lymphatic system disorders


disorders of the immune system

Hypersensitivity including anaphylaxis has been reported.

endocrine disorders

Suppression of the HPA axis.


Limited carbohydrate intolerance with increased need for antidiabetic therapy, manifestation of latent diabetes mellitus.

Metabolic and nutritional disorders

Sodium and water retention, hypokalemia, hypokalemic alkalosis, increased appetite, negative protein and calcium balance.

Mental disordersA

Euphoric mood, drug addiction, depressed mood, insomnia, schizophrenia.

Diseases of the nervous system

dizziness, headache.


eye diseases

Glaucoma, papilledema, subcapsular cataract, central serous chorioretinopathy, proptosis, corneal or scleral thinning, exacerbation of ophthalmic viral or fungal diseases and blurred vision (see also section 4.4).

Diseases of the ear and labyrinth


heart diseases

Myocardial rupture after recent myocardial infarction.

Congestive heart failure (in susceptible patients).


vascular diseases

hypertension, embolism.

Respiratory, thoracic and mediastinal disorders


Gastrointestinal Disorders

Dyspepsia, nausea, vomiting, abdominal distension, abdominal pain, diarrhea, esophageal ulceration, candidiasis, acute pancreatitis.

Gastric ulcer with perforation and bleeding.

Diseases of the skin and subcutaneous tissue

Skin atrophy, skin striae, acne, telangiectasia, hyperhidrosis, rash, itching, urticaria, hirsutism.

Diseases of the musculoskeletal system and connective tissue

Myopathy, osteoporosis, vertebral and tubular bone fractures, avascular osteonecrosis, myalgia.

Diseases of the kidneys and urinary tract

scleroderma-kidney crisis*

Disorders of the reproductive system and breast

Menstruation irregular, amenorrhea.

General disorders and administration site conditions

Impaired healing, malaise.


weight gained.

Injuries, poisoning and procedural complications

Tendon rupture, contusion (bruise).

*After high doses

a) A wide spectrum of psychiatric reactions, including mood disorders (such as irritability, euphoria, depressed and unstable mood, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, and exacerbation of schizophrenia), behavioral disorders, irritability, anxiety, sleep It became over Disorders and cognitive dysfunction including confusion and amnesia have been reported. Reactions are common and can occur in both adults and children. In adults, the frequency of severe reactions has been estimated at 5-6%. Psychological effects have been reported upon withdrawal of corticosteroids; the frequency is unknown.

*Scleroderma-kidney crisis

The occurrence of scleroderma renal crisis varies among the different subpopulations. The highest risk has been reported in patients with diffuse systemic sclerosis. The lowest risk was reported in patients with limited systemic sclerosis (2%) and juvenile systemic sclerosis (1%).

withdrawal symptoms

Reducing the dose of corticosteroids too quickly after prolonged treatment can result in acute adrenal insufficiency, hypotension and death (see section 4.4).

"Withdrawal syndrome" may also occur, including fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules, and weight loss.

In some cases, withdrawal symptoms may include or resemble clinical relapse of the disease for which the patient was being treated.

Other side effects that may occur during discontinuation or switching of corticosteroid therapy are benign intracranial hypertension with headache and vomiting, and papilledema caused by cerebral edema.

Latent rhinitis or eczema can be unmasked.

Pediatric population:

Increased intracranial pressure with papilledema in children (pseudotumor cerebri) - usually after discontinuation of treatment.

Growth retardation in infancy, childhood and adolescence.

Reporting suspected side effects

It is important to report suspected side effects after the medicine has been approved. It allows continuous monitoring of the benefit-risk balance of the drug. Healthcare professionals are encouraged to report any suspected adverse reactions through the Yellow Card Scheme

Website: or search for MHRA Yellow Card on Google Play or Apple App Store.

4.9 Overdose

In the event of an acute overdose, treatment is unlikely to be necessary.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: glucocorticoids, ATC code: H02AB06

Prednisolone soluble tablets contain the equivalent of 5 mg of prednisolone in the form of the 21-disodium phosphate ester. Prednisolone sodium phosphate is a synthetic glucocorticoid with the same general properties as prednisolone itself and other compounds classified as corticosteroids. Prednisolone is four times more active than hydrocortisone by weight.

Prednisolone sodium phosphate is very soluble in water and therefore less likely to cause local gastric irritation than prednisolone alcohol, which is only slightly soluble. This is important when high dosages are required, such as in immunosuppressive therapy.

5.2 Pharmacokinetic properties


Prednisolone is readily absorbed from the gastrointestinal tract, with peak plasma concentrations occurring 1-2 hours after an oral dose. Plasma prednisolone is mainly protein bound (70-90%), with binding to albumin and corticosteroid-binding globulin. The plasma half-life of prednisolone is between 2.5 and 3.5 hours after a single dose.


(Video) Webinar: Understanding mechanisms of drugs toxicity using hepatocytes-based spheroids.

The volume of distribution and clearance of total prednisolone and unbound prednisolone are concentration dependent and this has been attributed to saturable protein binding over the therapeutic plasma concentration range.


Prednisolone is extensively metabolised, mainly in the liver, but the metabolic pathways are not well defined.


Over 90% of the prednisolone dose is excreted in the urine, with 7-30% recovered as free prednisolone and the remainder as various metabolites.

5.3 Preclinical safety data

No other relevant data.

6. Pharmaceutical claims
6.1 List of excipients

sodium acid citrate


Saccharin Natrium


Sodium benzoate (E 211)

Erythrosin (E127)

6.2 Incompatibilities

Not applicable.

6.3 Durability

2 years.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of the container

The tablets are wrapped in foil strips and are supplied in cartons of 30 tablets.

6.6 Special precautions for disposal and other handling

Any unused medicine or waste materials should be disposed of in accordance with local requirements.

7. Marketing Authorization Holder

Fokus Pharmaceuticals Ltd

main house,

85 Koenig-Wilhelm-Strasse,

London EC4N 7BL,

Great Britain.

8. Registration number(s)

PL 20046/0261

9. Date of initial authorisation/renewal of authorisation


10. Date of revision of the text



Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (21)


Capital House, 1. Stock, 85 King William Street, London, EC4N 7BL, UK


+44 (0)208 588 9131

Direct call for medical information

+44 (0)208 588 9131

E-mail with medical information

[Email Protected]

Direct line to customer service

+44 (0)208 588 9273

  • Contact us
  • connections
  • Accessibility
  • Legal information and data protection
  • Cookie Settings
  • glossary
  • Sitemaps

Delivered by Prednisolone 5 mg soluble tablets - Summary of Product Characteristics (SmPC) (22)

(Video) Drug repurposing - John Overington


What is prednisolone 5mg soluble tablets used for? ›

Prednisolone Soluble Tablets may be given early in the treatment of acute asthma attacks in children. For children over 5 years use a dose of 30-40mg prednisolone.

What is soluble prednisolone used for? ›

Prednisolone soluble tablets belong to a group of medicines called corticosteroids ('steroids'). Steroids work by reducing inflammation, swelling and irritation in your mouth. Prednisolone soluble tablet used as a mouthwash may help reduce inflammation and pain in your mouth, and speed up the healing process.

How long does it take for prednisolone 5mg tablets to work? ›

You might feel better after a couple of days of taking prednisolone. But it depends on your illness. For some illnesses, you may not notice any difference in how you feel after you start taking prednisolone. This does not mean the medicine is not working.

What are the side effects of prednisolone 5mg tablets? ›

Common side effects
  • Weight gain. If you have to take prednisolone for more than a few weeks, it's likely that you'll put on weight. ...
  • Indigestion. Take prednisolone with food to reduce the chances of stomach problems. ...
  • Problems sleeping (insomnia) ...
  • Feeling restless. ...
  • Sweating a lot. ...
  • Mild mood changes.

What infections does prednisolone treat? ›

What Conditions does Prednisolone Treat?
  • rejection of a transplanted organ.
  • infection caused by the trichinae parasite.
  • sarcoidosis.
  • pneumonia with a fungus called Pneumocystis jirovecii.
  • diagnostic test for Cushing's syndrome.
  • increased calcium in the blood from sarcoidosis.

What happens when you take prednisolone? ›

Nausea, heartburn, headache, dizziness, menstrual period changes, trouble sleeping, increased sweating, or acne may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

What is the difference between prednisone and prednisolone tablets? ›

Prednisolone and prednisone are corticosteroid medications. They can treat health conditions involving an overactive immune system, allergies, and more. Prednisone is a prodrug, meaning it chemically changes in your body after you swallow it. It then turns into its active form, prednisolone.

How long does soluble prednisolone take to work? ›

You can give the mixture to your child using an oral syringe or spoon. When should the medicine start working? Prednisolone should start to help your child's wheezing soon after taking it, but usually takes 4–6 hours to have its full effect.

How long does prednisolone take to work for inflammation? ›

Prednisone generally works very quickly — usually within one to four days — if the prescribed dose is adequate to reduce your particular level of inflammation. Some people notice the effects of prednisone hours after taking the first dose.

Does prednisolone 5mg make you sleepy? ›

Prednisone does not usually cause sleepiness but may make you feel dizzy, irritable with mood swings, or cause you to have trouble sleeping (insomnia). If your dose is stopped too quickly or if you take prednisone for a long period of time you may feel severely fatigued.

What is the best time to take prednisolone 5mg? ›

Unless your doctor or pharmacist gives you different instructions, it's best to take prednisolone as a single dose once a day, with breakfast. For example, if your dose is 40mg daily, your doctor may tell you to take 8 tablets (8 x 5mg) all at the same time.

Is prednisolone a strong steroid? ›

What is prednisone? Prednisone is a strong anti-inflammatory steroid and jack-of-all-trades that is prescribed to treat conditions such as: Poison ivy. Sore throat.

How long can you take 5mg prednisone? ›

Official answer. There is no set limit on how long you can safely take prednisone.

Is 5mg of prednisone strong? ›

In general: Low dose: less than 7.5 mg per day. Moderate dose: between 7.5 mg and 40 mg per day. High dose: 40 mg to 60 mg per day.

Does prednisone affect urination? ›

Prednisone & prednsolone have activity in the kidney leading to the conservation of salt. This creates the classical side effects of prednisone/prednisolone use: excessive thirst and excessive urination.

Why would a doctor prescribe prednisolone? ›

Prednisolone is a medicine used to treat a wide range of health problems including allergies, blood disorders, skin diseases, inflammation, infections and certain cancers and to prevent organ rejection after a transplant. It helps by reducing swelling (inflammation) and can also calm down your immune system.

What should I avoid while taking prednisone? ›

Prednisone has a tendency to raise the level of glucose, or sugar, in the blood, which can cause increased body fat or diabetes in some people. It is important to avoid "simple" carbohydrates and concentrated sweets, such as cakes, pies, cookies, jams, honey, chips, breads, candy and other highly processed foods.

What not to take with prednisone? ›

Some products that may interact with this drug include: aldesleukin, mifepristone, drugs that can cause bleeding/bruising (including antiplatelet drugs such as clopidogrel, "blood thinners" such as dabigatran/warfarin, NSAIDs such as aspirin/celecoxib/ibuprofen).

How does prednisone make you feel when you take it? ›

Early in treatment (within several days), prednisone may increase feelings of well-being, anxiety, hypomania or mild euphoria. With long-term therapy, however, people may develop depression. Psychosis, referred to as corticosteroid-induced psychosis, can occur at doses of 20 mg or more per day with long-term use.

How do you feel after taking prednisone? ›

Common short-term side effects include changes in appetite, mood, energy, and sleep. Long-term prednisone treatment can lead to weight gain, osteoporosis, and cataracts. Diarrhea is not a side effect of prednisone. But other gastrointestinal symptoms are possible, like increased appetite and indigestion.

Does prednisone help with pain? ›

Prednisone, like other corticosteroids, quickly lowers inflammation, which cuts down on pain, redness, and swelling. It also dials down your immune system. Under normal conditions, this system protects you against things like viruses and bacteria that cause infections and diseases.

What anti-inflammatory is stronger than prednisone? ›

Methylprednisolone is more potent than prednisone. Doctors can give methylprednisolone orally or through an injection, while prednisone is only available as an oral treatment.

Is prednisone better than anti-inflammatory? ›

Prednisone, a glucocorticoid steroid, is a much more potent anti-inflammatory. A blood test, the ESR, almost always is high in people with PMR. Although prednisone dramatically improves PMR, it needs to be taken for one to two years (sometimes longer) in most people and can cause many side effects.

How long can you take prednisone for arthritis? ›

Continue to take prednisone tablets regularly until your doctor tells you otherwise. You may need to take them for several months, or even longer. Stopping suddenly can cause problems and your doctor may want you to reduce your dose gradually if this is necessary.

How do I know if prednisolone is working? ›

Prednisone usually works very quickly, within a few hours to days of taking the first dose depending on the condition you are treating. If the prescribed dose of prednisone is effective at reducing your inflammation, then you may notice an effect within hours.

How many prednisone 5mg can I take a day? ›

Oral: 10 to 60 mg/day given in a single daily dose or in 2 to 4 divided doses; Low dose: 2.5 to 10 mg/day; High dose: 1 to 1.5 mg/kg/day (usually not to exceed 80 to 100 mg/day).

How long does it take to recover from prednisolone? ›

A full recovery can take a week to several months. Contact your doctor if you experience prednisone withdrawal symptoms as you are tapering off the drug.

Will 5mg prednisone help inflammation? ›

It is known and has been repeatedly demonstrated that low doses of prednisone or prednisolone (10 mg daily or 5 mg bid) will control most of the inflammatory features of early polyarticular rheumatoid arthritis (Table 2).

Can inflammation come back after prednisone? ›

Your symptoms may be a return of inflammation, not withdrawal. Tapering too quickly can cause a flare to happen. If your disease flares, you may need to go back to a higher steroid dose for a short time to get the inflammation under control.

Does prednisone get rid of all inflammation? ›

Steroid drugs, such as prednisone, work by lowering the activity of the immune system. The immune system is your body's defense system. Steroids work by slowing your body's response to disease or injury. Prednisone can help lower certain immune-related symptoms, including inflammation and swelling.

Does prednisolone give you energy? ›

Prednisone can cause an increase in energy. You may also develop insomnia, or difficulty sleeping. Taking the medication in the morning may help to prevent this.

Does prednisolone keep you up at night? ›

Prednisone is a steroid medication that can cause side effects, including insomnia. People taking this medication may have difficulty falling asleep or stay awake through the night.

Can I take prednisolone before sleep? ›

If you are on daily prednisone, experts recommend taking the dose in the morning, to reduce this risk. Taking prednisone too late in the evening can cause sleeplessness and insomnia, too.

What happens if you take prednisone before bed? ›

It can cause some degree of insomnia in 50 to 70 percent of those who take it, but the higher the dose, the more likely the insomnia. It sounds like crazy advice, but many of my patients have had luck following my recommendation to take the prednisone immediately before bedtime.

Does prednisone make your lungs stronger? ›

The review reports that oral steroids may improve lung function, reduce shortness of breath, and result in lower relapse rates for people with moderate and severe COPD exacerbations. One of the most significant concerns about oral corticosteroids is how long a person should take them for.

Does prednisone raise blood pressure? ›

Prednisone raises blood pressure in many people who take it. One reason is that prednisone and other corticosteroids cause the body to retain fluid. Extra fluid in the circulation can cause an increase in blood pressure.

Does prednisone affect kidneys or liver? ›

Conclusions. This study shows that prednisolone decreases inflammation and improves renal function, whilst not reducing liver injury.

Does your body go back to normal after prednisone? ›

A gradual reduction in prednisone dosage gives your adrenal glands time to resume their usual function. The amount of time it takes to taper off prednisone depends on the disease being treated, the dose and duration of use, and other medical considerations. A full recovery can take a week to several months.

Who shouldn't take prednisone? ›

Who may not be able to take prednisolone tablets and liquid
  • have ever had an allergic reaction to prednisolone or any other medicine.
  • have an infection (including eye infections) or any unhealed wounds.
  • are trying to get pregnant, are already pregnant or you are breastfeeding.

Does prednisone help with pain or just inflammation? ›

What Does Prednisone Do? Prednisone, like other corticosteroids, quickly lowers inflammation, which cuts down on pain, redness, and swelling. It also dials down your immune system. Under normal conditions, this system protects you against things like viruses and bacteria that cause infections and diseases.

Does prednisone help you sleep at night? ›

In some studies, more than 60% of people using prednisone reported insomnia. People who take this medication may find that it takes longer to fall asleep or that they wake frequently during the night. They may also sleep for shorter periods and find that overall sleep quality is lower.

Why does prednisone make me feel so good? ›

Prednisone affects areas of the brain that manage the regulation of different neurotransmitters, including serotonin and dopamine — the “feel-good” hormones. Feeling happy is a great side effect some people feel with prednisone.


1. Session II - Managing Complex HIV Patients - European Edition
(Academic Medical Education)
2. Opioid Choices and Issues for Patient and Practitioner
(Optometric Education Consultants)
3. ✅ Amino Acids: Best Amino Acids 2021 (Buying Guide)
(Review Tube)
5. Short Review Of Orodispersible Tablets By Dr. AHK
(Ham Times)
6. heart
(Jignesh Danidhar)


Top Articles
Latest Posts
Article information

Author: Neely Ledner

Last Updated: 10/08/2023

Views: 5701

Rating: 4.1 / 5 (62 voted)

Reviews: 93% of readers found this page helpful

Author information

Name: Neely Ledner

Birthday: 1998-06-09

Address: 443 Barrows Terrace, New Jodyberg, CO 57462-5329

Phone: +2433516856029

Job: Central Legal Facilitator

Hobby: Backpacking, Jogging, Magic, Driving, Macrame, Embroidery, Foraging

Introduction: My name is Neely Ledner, I am a bright, determined, beautiful, adventurous, adventurous, spotless, calm person who loves writing and wants to share my knowledge and understanding with you.